[Antithrombotic therapy of acute coronary syndromes].
Recent advances in the diagnosis and the treatment of acute coronary syndromes (ACS) have led to a substantial reduction of major coronary events, to an improvement in patient outcome and the definition of new guidelines. Current strategies for the treatment of patients with non-ST-elevation ACS recommend a combined antithrombotic therapy (including aspirin, clopidogrel, anticoagulation with low-molecular weight or unfractionated heparins or FXa-inhibitors or direct antithrombins and, eventually glycoprotein IIb/IIIa receptor antagonists). This combined antithrombotic therapy allows to increase the benefit of an early invasive strategy including coronary angiogram with stent percutaneous coronary angioplasty. The purpose of this review is to discuss and highlight the recommendations for the appropriate use of antithrombotic strategies in the setting of angioplasty in ACS patients.
Hölschermann
H
H
Medizinische Klinik I, Kardiologie und Angiologie, Medizinische Klinik I, Hochtaunus-Kliniken, Urselerstrasse 33, 61348 Bad Homburg. hans.hoelschermann@hochtaunus-kliniken.de
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D015912:Thrombolytic Therapy / Q000379:methods*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin